Labiotech.eu

In recent years, biopharma has paid significantly different prices for the same underlying technology. In March 2025, AstraZeneca agreed to pay EsoBiotec, an in vivo CAR-T platform with early single-patient data, $425 million upfront and up to $575 million more in milestones. In August 2025, Gilead’s Kite paid $350 million for Interius BioTherapeutics, another in vivo CAR-T platform, also lentivi…

What if the key to beating cancer was a new way of thinking about matter? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago The post Beyond biology: Nanobiotix’s physics-first approach to cancer appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from …

Geneva’s life science industry is bound to western Switzerland's Health Valley ecosystem but is also growing in and of itself. The post Life science industry in Geneva on a roll appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Ex…

BIO-Europe 2026 heads to Cologne this November, expanding from three tracks to seven to reach the full biotech and pharma C-suite. The post BIO-Europe 2026: Expanding the scope at Europe’s leading biotech partnering event appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s au…

Discover 8 biotech companies in Melbourne, ranging from commercial to preclinical-stage companies, advancing promising technologies. The post Eight biotech companies in Melbourne you should know about appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is …

Labiotech's reader survey reveals what our audience wants, needs, and is interested in for 2026. The post We asked, you answered: Labiotech’s 2026 reader survey results appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts an…

Discover how UCB’s pipeline strategy in 2026 is still focused on its core areas of immunology and neurology. The post UCB’s pipeline strategy in 2026: Doubling down on immunology and neurology appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly…

In this article, we take a look at seven clinical-stage biotechs that are fostering R&D in the Duchenne muscular dystrophy therapeutic space. The post Seven biotechs driving progress in Duchenne muscular dystrophy appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and…

The CBO CEO relationship shapes biotech deal success. Discover insights from 19 industry leaders on board alignment and partnering. The post We asked 19 biotech leaders what breaks their deals. It wasn’t the science. appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author …

The top biotech deals of July 2026 were over small molecules, cell therapies, antibodies, RNA therapeutics, vaccines, and AI. The post Top biotech deals in July 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and l…

The companies BridgeBio, Erasca, Chai Discovery, and MeiraGTx bagged the biggest biotech funding rounds overall in July 2026. The post The biggest biotech funding rounds in July 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibite…

We look at some of the top companies that are investigating CAR-T therapies in clinical trials for autoimmune diseases. The post Eight CAR-T companies tackling autoimmune disorders appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited.…

Learn why cryopreservation is becoming essential for scalable, standardized cell therapy manufacturing and commercialization. The post Cryopreservation in cell therapy: Reducing variability from the start appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner…

While Japan historically lacked foreign investment, the field is becoming more dynamic. Discover ten essential biotech companies in Japan. The post 10 biotechs in Japan to watch in 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohib…

Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry. The post Merck after Keytruda: what the pipeline looks like appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excer…

Today we welcome Gene Mack, President and CEO of Gain Therapeutics. Their lead candidate is advancing toward Phase 2 as a potential first-in-class disease-modifying therapy for Parkinson’s disease The post Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this mate…

About half the people with gout don't have treatments that work for them. New drugs in the clinic could address this underserved population. The post Meeting unmet needs: new treatments for gout race in the clinic appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and…

CNS drug development lags far behind oncology, but translationally relevant mouse models can help close that gap and improve trial outcomes. The post Mouse models and CRO selection critical to de-risking neurology drug development appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this …